OSAKA, Japan, July 12, 2011 – Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it entered into licensing agreement for the sale of pirfenidone in South Korea with ILDONG PHARMACEUTICAL Co., Ltd. (Head Office: Seoul; Chairman & CEO: Jung-chi Lee; hereafter “ILDONG”) on May 30, 2011. Following the execution of agreement, ILDONG will file a New Drug Application and exclusively sell this product in South Korea.
Shionogi received marketing and manufacturing approval for pirfenidone in Japan for the treatment of idiopathic pulmonary fibrosis (IPF) in October, 2008, and launched it as “Pirespa®” in December of that year. Japan is the first country in which pirfenidone has been approved. Pirfenidone is a promising therapeutic agent which is expected to inhibit the progression of IPF through a new mechanism of action inhibiting fibrosis directly and offering a new option for IPF treatment.
Read entire article at:
Visit www.ipftoday.com for more info on Pulmonary Fibrosis